Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:

"Today's approval of pembrolizumab (Keytruda) in...

Photograph of a patient receiving cancer treatment
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

A new drug is approved for treating triple negative locally advanced and secondary (metastatic) breast cancer.

House of Commons
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

The Health and Care Bill received Royal Assent on 28 April 2022, meaning it has now become law. Unfortunately, we don't think it went far enough to help cancer patients.

A close up of one hand holding another in a comforting manner
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

Tracey and Elizabeth­­­­­­­ were both diagnosed with breast cancer during the pandemic and agreed to share their experiences with the Health and Social Care Select Committee’s Expert Panel as part of its evaluation into the government’s commitments on cancer services in England.

jen and clare
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

For 15 years, Breast Cancer Now has been campaigning for better information on those living with secondary breast cancer. We still don't have the statistics we need, but we are determined to see improvements.

PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

Today, Steve Brine MP tabled a ten minute rule bill on how breast screening can increase early diagnosis. In this blog we take a look at some of...

On 16 March new findings from the OlympiA phase III trial were presented at a virtual plenary session from the European Society of Medical Oncology....

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:

“It’s alarming that in January, for the first time, less than half...

Background

The National Institute for Health and Care Excellence (NICE) has today (Tuesday 8th March 2022) announced its provisional...

Background

The Scottish Medicines Consortium (SMC) has today announced its decision to recommend Trodelvy for use on the NHS in Scotland...